Celia Belline, Co-founder and CEO of Cilcare, was recently invited on the BIO from the BAYOU podcast to discuss a topic that is rapidly gaining recognition across the scientific and medical communities: the central role of hearing health in preventing cognitive decline. In a thoughtful conversation with Elaine Hamm, CEO of Ascend BioVentures, Celia highlights a belief that has guided Cilcare since its inception — that hearing loss is not only a sensory impairment but a crucial early indicator of brain health.
Throughout the episode, Celia shares how Cilcare has long been at the forefront of acknowledging the strong connection between auditory function and neurodegeneration, well before it became a focus in public health strategies. She emphasizes the need to recognize hearing as a key biomarker in assessing aging and cognitive disorders. This vision has driven Cilcare to build unique, science-driven approaches combining therapeutic innovation, advanced auditory assessment, and strategic collaborations with leading industry and academic partners.
About BIO from the BAYOU
BIO from the BAYOU is a podcast dedicated to exploring innovation, entrepreneurship, and scientific breakthroughs in the life sciences sector. Hosted by Dr. Elaine Hamm, the show features candid conversations with leaders, founders, and scientists shaping the future of biotechnology and health. Each episode highlights emerging trends, research insights, and inspiring stories from across the global biotech ecosystem, providing listeners with an accessible and in-depth look at the ideas driving progress in human health.
About Cilcare
Cilcare is a biotechnology company specialising in auditory sciences, dedicated to developing cutting-edge solutions for the characterisation, diagnosis, and treatment of hearing disorders and related diseases. Founded by three visionary entrepreneurs, the company now brings together a team of 45 international experts, supported by a scientific advisory board. Since its inception in 2014, Cilcare has been tackling global hearing health challenges by combining an advanced R&D platform, a promising pipeline of drug candidates, and the power of artificial intelligence and machine learning to better characterise different forms of hearing loss. For the past 10 years, Cilcare has also been providing its technology to industry leaders and researchers in Europe, the United States, and Asia, helping accelerate the development of drugs, gene and cell therapies, and medical devices for hearing disorders.
For more information, visit www.cilcare.com.
Â
